Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01092312 · ClinicalTrials.gov registry record · NA
Signature Personalised Patient Care System With the Vanguard Knee System Study
A NA study, sponsored by Zimmer Biomet.
- Terminated
- Registry status
- NA
- Development phase
- 325
- Enrollment target
NCT01092312: Clinical Trial NA study, sponsored by Zimmer Biomet.
NCT01092312 is a NA study that was terminated before completion, run by Zimmer Biomet. The registered enrollment target is 325 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01092312, a NA study, was terminated before completion, sponsored by Zimmer Biomet.
- TERMINATED
- Registry status
- NA
- Development phase
- 325 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the percentage cases which have ideal mechanical axial alignment using the Vanguard total Knee implant with the Signature cutting blocks is higher than those without the use of Signature when measured immediately post-operatively.
Primary Outcome
Femoral and tibial component alignment, femoral and tibial rotational alignment, tibial posterior slope
Interventions
- PROCEDURE Vanguard Knee System with Signature Knee Guide
- PROCEDURE Vanguard Knee System with conventional Instruments
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 325 participants |
| Start Date | 2010-03 |
| Est. Completion | 2016-09 |
| Phase | NA |
Why NCT01092312 stopped before completion
NCT01092312 is an interventional study that assigns participants to a tested intervention. The registered 325 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 2 interventions - of which Vanguard Knee System with Signature Knee Guide is the first listed.
NCT01092312 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01092312 about?
NCT01092312 is a clinical study titled "Signature Personalised Patient Care System With the Vanguard Knee System Study". The purpose of this study is to determine whether the percentage cases which have ideal mechanical axial alignment using the Vanguard total Knee implant with the Signature cutting blocks is higher than those without the use of Signature when measured immediately post-operatively.
What is the current status of trial NCT01092312?
This trial is currently terminated. It is a NA study. The enrollment target is 325 participants. The study started on 2010-03. Estimated completion is 2016-09.
What interventions are being tested in trial NCT01092312?
The interventions under investigation include: Vanguard Knee System with Signature Knee Guide (PROCEDURE), Vanguard Knee System with conventional Instruments (PROCEDURE).
Who is sponsoring clinical trial NCT01092312?
This trial is sponsored by Zimmer Biomet, which has 115 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01092312's enrollment target sits among peer trials
325 311th of 2000 higher than 1,689 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02543983 · 325 participants · Phase 2
Neurobiology of Suicide
- NCT03016819 · 325 participants · Phase 3
Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)
- NCT03288207 · 325 participants · NA
Tailoring Mobile Health Technology to Reduce Obesity and Improve Cardiovascular Health in Resource-Limited Neighborhood Environments
- NCT04986657 · 325 participants · NA
Whole Genome Sequencing (ChromoSeq) as an Adjunct to Conventional Genomic Profiling in AML and MDS
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia